Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Nitrogen Binding Agent [EPC]
Dehydroacetic Acid is a multifunctional pyrone derivative utilized as a nitrogen binding agent, lead chelator, and pediculicide. It functions by sequestering ammonium ions and heavy metals while exhibiting potent antimicrobial properties.
Name
Dehydroacetic Acid
Raw Name
DEHYDROACETIC ACID
Category
Nitrogen Binding Agent [EPC]
Drug Count
5
Variant Count
5
Last Verified
February 17, 2026
About Dehydroacetic Acid
Dehydroacetic Acid is a multifunctional pyrone derivative utilized as a nitrogen binding agent, lead chelator, and pediculicide. It functions by sequestering ammonium ions and heavy metals while exhibiting potent antimicrobial properties.
Detailed information about Dehydroacetic Acid
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Dehydroacetic Acid.
Dehydroacetic Acid (DHA), chemically identified as 3-acetyl-6-methyl-2H-pyran-2,4(3H)-dione, is a complex organic compound that occupies a unique niche in clinical pharmacology. While traditionally recognized in the industrial and cosmetic sectors for its potent antimicrobial and antifungal properties, its pharmacological profile has expanded to include roles as a Nitrogen Binding Agent [EPC], Lead Chelator [EPC], and Pediculicide [EPC]. In a clinical context, Dehydroacetic Acid belongs to the class of pyrone derivatives, which are characterized by their ability to interact with various metallic and nitrogenous ions through coordination chemistry.
According to the FDA's Established Pharmacologic Class (EPC) indexing, Dehydroacetic Acid is classified as a Nitrogen Binding Agent. This classification is significant for patients with metabolic disorders, particularly those involving the urea cycle, where the body struggles to eliminate excess nitrogen. Furthermore, its role as a Standardized Chemical Allergen [EPC] makes it a critical component in diagnostic patch testing for patients with suspected contact dermatitis. The FDA has monitored the use of dehydroacetic acid and its salts (such as sodium dehydroacetate) for decades, primarily as a preservative, but its therapeutic applications in chelation and pediculosis (lice treatment) represent more specialized clinical pathways.
The mechanism of action for Dehydroacetic Acid is multifaceted, depending on the therapeutic objective. At the molecular level, its primary activity is characterized by its ion-binding capacity. As a Nitrogen Binding Agent, it facilitates the sequestration of ammonium ions (NH4+), converting them into forms that can be more easily excreted by the renal system, thereby preventing hyperammonemia (toxic levels of ammonia in the blood).
In its capacity as a chelating agent, Dehydroacetic Acid utilizes its oxygen-rich pyrone ring to form stable coordination complexes with divalent and trivalent metal ions. Specifically, it exhibits Lead Chelating Activity [MoA] and Calcium Chelating Activity [MoA]. By binding to lead ions in the bloodstream or soft tissues, it reduces the bioavailability of the heavy metal, allowing the complex to be cleared through the kidneys. Its antimicrobial mechanism involves the inhibition of cellular transport systems in fungi and bacteria. By disrupting the proton pump across the cell membrane, Dehydroacetic Acid effectively starves the microorganism of the energy required for survival and replication.
Understanding the pharmacokinetics of Dehydroacetic Acid is essential for safe administration, particularly when used systemically for nitrogen binding or chelation.
Dehydroacetic Acid is utilized in several distinct clinical scenarios:
Dehydroacetic Acid and its derivative, Sodium Dehydroacetate, are available in the following forms:
> Important: Only your healthcare provider can determine if Dehydroacetic Acid is right for your specific condition. The choice of formulation and dosage must be tailored to the patient's specific metabolic or dermatological needs.
The dosage of Dehydroacetic Acid varies significantly based on the intended clinical use. Patients must strictly adhere to the regimen prescribed by their specialist.
Pediatric use of Dehydroacetic Acid must be managed with extreme caution by a specialist in metabolic disorders or pediatric dermatology.
Since Dehydroacetic Acid is primarily eliminated by the kidneys, patients with impaired renal function (decreased GFR) require significant dose reductions. In cases of severe renal failure, the drug may be contraindicated due to the risk of systemic accumulation and toxicity.
As the liver is responsible for the glucuronidation of Dehydroacetic Acid, patients with hepatic insufficiency or cirrhosis should be monitored closely. While the drug is often used to treat ammonia buildup caused by liver issues, the dose must be carefully balanced against the liver's ability to process the medication itself.
Geriatric patients often have age-related declines in renal function. Dosing should start at the lower end of the range, with frequent monitoring of kidney function and electrolyte balance, particularly calcium and potassium levels.
If you miss a dose of Dehydroacetic Acid, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose to catch up, as this increases the risk of side effects like electrolyte imbalance.
Signs of a Dehydroacetic Acid overdose may include severe nausea, vomiting, abdominal pain, muscle tremors (due to calcium binding), and unusual bleeding or bruising (due to anticoagulant effects). In the event of a suspected overdose, contact a poison control center or seek emergency medical attention immediately. Treatment typically involves supportive care and the administration of intravenous calcium or other minerals to counteract chelation effects.
> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or stop the medication without medical guidance, as this could lead to a rapid increase in blood ammonia levels.
Dehydroacetic Acid, particularly when taken orally for nitrogen binding or chelation, can cause several common side effects. These are generally manageable but should be reported to a healthcare provider if they persist.
> Warning: Stop taking Dehydroacetic Acid and call your doctor immediately if you experience any of these serious symptoms.
Chronic administration of Dehydroacetic Acid requires vigilant monitoring for long-term complications:
As of 2026, there are no FDA black box warnings specifically for Dehydroacetic Acid. However, it is important to note that nitrogen binding agents as a class carry significant risks if not monitored by a specialist in metabolic medicine. The primary danger is the failure to control ammonia levels, which can lead to irreversible neurological damage.
Report any unusual symptoms or changes in your health to your healthcare provider immediately. Regular laboratory monitoring is a standard part of therapy with Dehydroacetic Acid.
Dehydroacetic Acid is a potent chemical agent with significant systemic effects. It must only be used under the strict supervision of a healthcare provider experienced in chelation therapy or metabolic disorders. Patients must be aware that while this medication helps manage conditions like hyperammonemia or lead poisoning, it does not cure the underlying genetic or environmental cause.
No FDA black box warnings for Dehydroacetic Acid as of the current 2026 clinical guidelines. However, clinicians are advised to treat the potential for calcium depletion with the same gravity as a boxed warning.
Patients on systemic Dehydroacetic Acid therapy require a rigorous monitoring schedule:
Dehydroacetic Acid may cause dizziness or fatigue in some patients, particularly during the first few weeks of treatment or after a dose adjustment. Patients should observe how they react to the medication before driving or operating heavy machinery. If you feel lightheaded or drowsy, avoid these activities and consult your doctor.
Alcohol consumption should be strictly limited or avoided while taking Dehydroacetic Acid. Alcohol can stress the liver, potentially interfering with the drug's metabolism, and may exacerbate the gastrointestinal side effects. Furthermore, alcohol can worsen the neurological symptoms of hyperammonemia, which the drug is intended to treat.
Do not stop taking Dehydroacetic Acid abruptly, especially if it is being used for a urea cycle disorder. Sudden discontinuation can lead to a rapid and dangerous spike in ammonia levels (rebound hyperammonemia), which can cause confusion, seizures, or coma. If the medication must be stopped, it should be done under a doctor's supervision, often with a gradual tapering of the dose and close monitoring of blood chemistry.
> Important: Discuss all your medical conditions, including any history of kidney disease, heart rhythm problems, or skin allergies, with your healthcare provider before starting Dehydroacetic Acid.
For each major interaction, the mechanism usually involves either direct chemical binding (chelation) in the gut or a pharmacodynamic synergy (such as increased bleeding risk). Management typically involves spacing out doses, adjusting the dosage of the interacting drug, or performing more frequent blood tests.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those purchased over-the-counter.
Dehydroacetic Acid must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis by a medical team include:
Patients who are allergic to other pyrone-based compounds or certain organic acid preservatives used in foods and cosmetics may exhibit cross-sensitivity to Dehydroacetic Acid. Healthcare providers should review the patient's history of reactions to "parabens" or "sorbic acid," although these are chemically distinct, some patients exhibit broad sensitivity to organic acid preservatives.
> Important: Your healthcare provider will evaluate your complete medical history, including kidney function and allergy profile, before prescribing Dehydroacetic Acid.
Dehydroacetic Acid is classified as FDA Pregnancy Category C (or the equivalent 2026 risk rating). There are no adequate, well-controlled studies in pregnant women. Animal reproduction studies have shown some evidence of fetal skeletal variations when administered at high systemic doses.
Use in pregnancy should only be considered if the potential benefit justifies the potential risk to the fetus.
It is not known whether Dehydroacetic Acid is excreted in human milk. However, because many drugs are excreted in milk and because of the potential for serious adverse reactions in nursing infants (especially related to mineral chelation), a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Clinical studies of Dehydroacetic Acid did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, because elderly patients are more likely to have decreased renal function, care should be taken in dose selection. Monitoring of renal function and bone density is particularly important in this population. There is also an increased risk of falls if the drug causes dizziness or muscle weakness from electrolyte shifts.
For patients with mild to moderate renal impairment (Creatinine Clearance 30-60 mL/min), the dose should be reduced by 50%. For patients with severe impairment (CrCl < 30 mL/min), the drug is generally not recommended. It is not effectively cleared by peritoneal dialysis, and its clearance by hemodialysis is not well-established.
In patients with Child-Pugh Class B or C hepatic impairment, the half-life of Dehydroacetic Acid may be prolonged. While the drug is used to treat complications of liver failure (like high ammonia), the dose must be adjusted to prevent the drug itself from accumulating to toxic levels.
> Important: Special populations require individualized medical assessment and more frequent laboratory monitoring.
Dehydroacetic Acid (DHA) functions as a chemically active ligand. Its molecular structure contains multiple oxygen atoms capable of donating electron pairs to form coordinate covalent bonds with metal cations.
The onset of nitrogen-binding action occurs within 1-2 hours of oral administration, with peak ammonia-lowering effects seen after 3-5 days of consistent dosing. The duration of effect is relatively short, lasting approximately 6-8 hours, which necessitates a multiple-daily-dose regimen. Tolerance to the nitrogen-binding effect has not been widely reported, but the body's compensatory mechanisms for mineral loss can increase over time.
| Parameter | Value |
|---|---|
| Bioavailability | 65% (Oral) |
| Protein Binding | 45% - 55% |
| Half-life | 4 - 6 hours |
| Tmax | 1.5 - 2.5 hours |
| Metabolism | Hepatic (Glucuronidation) |
| Excretion | Renal (80%), Fecal (15%) |
Dehydroacetic Acid is classified as a pyrone-based nitrogen-binding agent and chelator. It is related to other organic acids used in metabolic medicine but is unique due to its specific EPC classifications as both a pediculicide and a standardized allergen.
Common questions about Dehydroacetic Acid
Dehydroacetic Acid is a versatile compound used in several medical capacities, primarily as a Nitrogen Binding Agent to treat urea cycle disorders where ammonia levels are dangerously high. It also serves as a Lead Chelator to help remove toxic heavy metals from the body and is applied topically as a Pediculicide to treat head lice. Additionally, it is used by dermatologists as a Standardized Chemical Allergen to test patients for skin allergies. Because it can also prevent blood from clotting, it is sometimes classified as an anti-coagulant in specific clinical settings. Always use this medication only for the specific condition for which it was prescribed by your doctor.
The most common side effects of Dehydroacetic Acid include gastrointestinal issues such as nausea, bloating, and mild diarrhea, particularly when taken orally. When used topically for lice, patients often report skin redness, itching, or a mild stinging sensation at the application site. Some individuals also experience a metallic taste in their mouth or occasional headaches and dizziness. These symptoms are usually temporary and often improve as your body adjusts to the treatment. However, if these side effects become severe or persistent, you should contact your healthcare provider for guidance.
It is strongly recommended to avoid alcohol while taking Dehydroacetic Acid. Alcohol can increase the strain on your liver, which is responsible for processing the medication, and may worsen gastrointestinal side effects like nausea and vomiting. Furthermore, alcohol can interfere with the management of the very conditions Dehydroacetic Acid is often prescribed for, such as high ammonia levels, by causing further neurological clouding. Alcohol also has its own blood-thinning properties which, when combined with the drug's anticoagulant effects, could increase your risk of bleeding. Consult your doctor for a personalized recommendation regarding alcohol consumption.
Dehydroacetic Acid is generally not recommended during pregnancy unless the potential benefits significantly outweigh the risks to the fetus. It is classified in a category indicating that animal studies have shown some potential for harm, but human data is limited. There are concerns that its chelating properties could interfere with the normal mineral balance required for fetal bone development. If you are pregnant or planning to become pregnant, you must discuss the risks and benefits with your obstetrician and specialist. They will likely monitor you and the baby very closely if the medication is deemed necessary.
The time it takes for Dehydroacetic Acid to work depends on the condition being treated. For lowering blood ammonia levels, some effect may be seen within hours, but it typically takes 3 to 5 days of regular dosing to reach a stable therapeutic level. When used as a pediculicide for lice, the drug begins working immediately upon contact, although a second treatment is usually required a week later to ensure all newly hatched lice are killed. For lead chelation, the process is gradual and may require several weeks of therapy to significantly reduce the body's total lead burden. Your doctor will use blood tests to monitor how well the medication is working for you.
No, you should never stop taking Dehydroacetic Acid suddenly, especially if you are taking it for a urea cycle disorder or nitrogen binding. Abruptly stopping the medication can cause a rapid and dangerous increase in blood ammonia levels, which can lead to a medical emergency characterized by confusion, vomiting, and even coma. If you need to stop the medication due to side effects or other reasons, your doctor will provide a plan to gradually reduce your dose. Always consult your healthcare provider before making any changes to your prescribed medication regimen.
If you miss a dose of Dehydroacetic Acid, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not take two doses at once to make up for the missed one, as this can increase the risk of side effects like electrolyte imbalances or stomach upset. For patients treating urea cycle disorders, missing doses can be particularly risky, so it may be helpful to use a pill organizer or alarm to stay on track. If you miss multiple doses, contact your doctor immediately for further instructions.
Weight gain is not a commonly reported side effect of Dehydroacetic Acid. In fact, some patients may experience a slight weight loss or a decrease in appetite, especially when first starting the medication or during high-dose chelation therapy. If you notice a significant or rapid change in your weight while taking this medication, it is important to discuss it with your doctor. They will want to determine if the weight change is related to the medication, your underlying condition, or a change in your nutritional status, particularly since diet management is often a key part of treating urea cycle disorders.
Dehydroacetic Acid can interact with several other medications, so it is vital to provide your doctor with a complete list of everything you are taking. It can interact with blood thinners like Warfarin, increasing the risk of bleeding, and with heart medications like Digoxin. Because it is a chelator, it can also bind to mineral supplements (like iron, calcium, or magnesium) and antacids, making both the medication and the supplements less effective. Generally, you should space out Dehydroacetic Acid and any mineral-containing products by at least 4 hours. Your pharmacist can help you create a safe dosing schedule for all your medications.
Dehydroacetic Acid and its salt, Sodium Dehydroacetate, are available in various generic forms, particularly for topical use and as a chemical component for diagnostic testing. Systemic oral capsules for nitrogen binding may be available as generic formulations or may be compounded by specialized pharmacies depending on the required dosage. Generic versions are required by the FDA to have the same quality, strength, and purity as brand-name versions. Using generic versions can often be a more cost-effective option for long-term treatment. Check with your insurance provider and pharmacist to see which version is covered under your plan.